Streetbeat News

BCTX

BriaCell Therapeutics Corp.

https://www.briacell.com

Industry

Biotechnology

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Open

3.73

Mkt cap

14M

Volume

62K

High

3.89

P/E Ratio

-0.29

52-wk high

7.87

Low

3.45

Div yield

N/A

52-wk low

0.35

BriaCell Therapeutics has received US FDA authorization for an Expanded Access Policy (EAP) to provide its treatment to metastatic breast cancer patients. This development could enhance the company's market presence and patient reach.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 11:51 am

The Nasdaq Composite surged over 200 points, driven by a rise in information technology shares. PureCycle Technologies, BriaCell Therapeutics, and Liquidia Corporation saw significant stock price increases due to positive company announcements. Conversely, Telesis Bio, Rentokil Initial, and Torrid Holdings experienced sharp declines following negative news. U.S. crude oil inventories rose slightly less than expected.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 6:30 pm

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating for BriaCell Therapeutics, maintaining a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 5:04 pm

BriaCell Therapeutics announced an $8.5 million best-efforts offering of 12.325 million common shares at $0.69 per share. The proceeds will be used for working capital, corporate purposes, and business advancement. The offering is expected to close on September 12, 2024.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 4:14 pm

U.S. stocks mostly fell with the S&P 500 down 0.5%. Notable stock movements include PureCycle Technologies up 32% after a financing update, BriaCell Therapeutics up 109% on positive clinical data, and Telesis Bio down 58% after announcing a delisting. Rentokil Initial shares fell 21% after revising guidance.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 4:13 pm

BriaCell Therapeutics (NASDAQ:BCTX) stock surged over 100% due to positive Phase 2 clinical study results for its Bria-IMT treatment in metastatic breast cancer, showing significant improvement in median overall survival rates.

Portfolio Pulse from Vandana Singh

September 11, 2024 | 3:08 pm

BriaCell Therapeutics shares were halted due to a circuit breaker as the stock surged by 166.3%.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 2:03 pm

U.S. stocks mostly fell with the Dow dropping 350 points, while the NASDAQ slightly rose. The U.S. inflation rate slowed to 2.5% in August. CN Energy, BriaCell Therapeutics, and Tantech Holdings saw significant stock price increases, while Telesis Bio, Laser Photonics, and Torrid Holdings experienced declines.

Portfolio Pulse from Avi Kapoor

September 11, 2024 | 1:47 pm

BriaCell Therapeutics shares have resumed trading, which may indicate a resolution of any previous issues that halted trading. Investors should monitor the stock for any further developments.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:46 pm

BriaCell Therapeutics shares experienced a trading halt due to a circuit breaker triggered by a sharp decline. Despite this, the stock is now up by 148.6%.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 1:41 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.